Max H. Yusem, Of Counsel, Litigation Department, Paul Hastings, LLP to Speak at The Knowledge Group’s Latest Hatch-Waxman Developments
The Knowledge Group, the leading producer of regulatory-focused webcasts, has announced today that Max H. Yusem, Of Counsel, Litigation Department, Paul Hastings, LLP will speak at its webcast entitled, “Orange Book Listings and Obviousness: Latest Hatch-Waxman Developments.”
- (1888PressRelease) May 17, 2025 - This event is scheduled for Thursday, May 29, 2025, from 12:00 PM to 1:00 PM ET.
For further details, please visit:
https://knowlearninghub.com/courses/orange-book-hatch-wax-cle/
About Max H. Yusem
Max Yusem is an of counsel in the Litigation practice of Paul Hastings and is based in the firm’s New York office. His practice focuses on complex litigation with an emphasis on intellectual property matters in the fields of pharmaceuticals and biotechnology.
Mr. Yusem has experience litigating cases arising under the Hatch-Waxman Act on behalf of innovator companies and the Biologics Price Competition and Innovation Act (BPCIA). He has represented leading life science companies in high-stakes disputes in district court litigations, patent office proceedings, and arbitrations involving pharmaceutical compounds, formulations, and methods of treatment, which involved a wide variety of therapeutics, covering areas such as cardiovascular, diabetes, oncology, central and peripheral nervous systems, hormone replacement, and hemoglobinopathy.
Mr. Yusem has also consulted and represented clients in numerous other areas including antibody technology, genetic testing, microfluidic devices, and ethanol processing. He received his law degree, with honors, from George Washington University School of Law in 2013, where he served on the George Washington International Law Review. He earned a Bachelor of Arts from the Department of Psychological and Brain Sciences at Johns Hopkins University in 2008. Mr. Yusem is admitted to the New York State Bar.
About Paul Hastings, LLP
Our globally- renowned IP litigation group consists of top-of-the-market litigators known throughout the industry to take on “bet-the-company” patent litigation claims, having tried to judgment some of the largest and most complex IP cases in the U.S. The practice’s deep bench of exceptionally talented and experienced litigators handles patent mandates that are of crucial commercial importance to clients. Our IP litigation capabilities extend across multiple forums, including all federal district courts, the ITC, the PTAB, the Federal Circuit, and arbitrational panels. Life Sciences patent litigation is a core strength of the practice and a highly specialized area in which only a very small number of firms truly compete at the highest level. Yet we remain an undisputed first choice for leading small-molecule drug and biologic makers in connection with business-critical IP disputes. The firm also represents many of the world’s largest innovator life sciences companies in high-stakes, high-value patent cases. In 2024 alone, our skilled litigators advised a range of companies on some of the biggest cases of the year and have been fearless in their pursuit of significant victories for our clients. Major new clients come to us specifically for our expertise in IP cases, and our reputation for taking on seemingly “unwinnable” cases and winning them.
Supported by a premier client portfolio and extensive industry experience, Paul Hastings is distinguished by the depth and breadth of its life sciences practice. The firm has a robust and growing nationwide presence, anchored on both coasts, with key offices in California, New York, Boston, Dallas, Houston, and Washington, D.C. Its multidisciplinary team advises a wide range of clients, including biotechnology and pharmaceutical companies, medical technology firms, healthcare organizations, and financial institutions investing in the sector—many of which it counsels on a nationwide basis.
Event Summary
Explore the latest developments in Hatch-Waxman litigation, with a deep dive into the legal and regulatory complexities surrounding Orange Book listings and the evolving obviousness standard in pharmaceutical patent law.
Join Jason A. Lief, Partner, at Windels Marx Lane & Mittendorf, LLP and Max H. Yusem, Of Counsel, Litigation Department, at Paul Hastings, LLP as they provide expert analysis and practical guidance based on recent court decisions, FDA actions, and real-world case studies. From Purdue v. Accord to Teva v. Amneal, this program will help attorneys and regulatory professionals navigate the shifting landscape of ANDA litigation, Orange Book strategy, and exclusivity protections.
Key Topics:
Key legal standards for obviousness in pharmaceutical patent cases, including KSR and Purdue v. Accord
Strategies for Orange Book listings, delisting requests, and managing Paragraph III/IV certifications
Recent FDA guidance and Federal Circuit rulings impacting Hatch-Waxman litigation
About The Knowledge Group
Founded in November 2006, The Knowledge Group has been at the forefront of providing quality continuing education programs for lawyers, accountants, financial executives, risk and compliance specialists, human resources professionals, technology officers, and business consultants in a wide range of industries.
The Knowledge Group strives to be the best-in-class provider of continuing education by bringing forth relevant content you can’t get anywhere else.
Contact:
Therese Lumbao
Director, Account Management & Member Services
The Knowledge Group, LLC
info ( @ ) theknowledgegroup dot org
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam